Volcano Cuts Deeper Into Peripheral Market With AtheroMed Buy
This article was originally published in The Gray Sheet
Volcano will pay $115 million, plus a potential milestone, for AtheroMed and its Phoenix atherectomy system, as part of the firm’s growing emphasis on the peripheral artery device market.
You may also be interested in...
"Pura Vida" – a Spanish phrase meaning the "pure" or "simple life" – isn't just the unofficial motto of Costa Rica; rather, it's a state of mind, locals say. But as more and more medical device manufacturing facilities pop up in the tiny Central American nation, quality assurance professionals there have discovered that ensuring top-notch product quality doesn't necessarily make life simpler. To jump that hurdle, QA experts from a variety of firms – including Medtronic, Precision Concepts and Creganna Medical – have banded together to lean on each other as they search for solutions to quality systems issues, as well as knowledgeable input on hot quality and compliance topics.
The imaging giant's $1.2 billion acquisition of intravascular assessment specialist Volcano deepens Philips' play in hospital cath labs and, Philips' CEO says in an interview, provides a combination of technology and know-how to create new catheter-based therapies for high-growth disease markets.
Device funding increased 123% to $1.6 billion in Q2, and M&A activity was overshadowed by Medtronic’s massive $47 billion acquisition of Covidien. Diagnostics fundraising dropped slightly to $522 million, and there were multiple takeovers of life sciences companies.